Lung-MAP represents an unprecedented approach to quickly gain information on which new drugs will be best suited to treat people with squamous cell lung cancer. We encourage everyone who is facing a diagnosis of squamous cell lung cancer to join this clinical trial. All participating patients will have their tumors tested for the mutations or other characteristics that drive the growth of their specific cancer, and then be matched to a clinical trial based on the results of those tests. All patients will receive the best possible care, whether that is through the best known chemotherapy options, or a new drug or set of drugs designed to attack their tumor’s particular characteristics.
-Regina Vidaver, Ph.D., Executive Director, Free to Breathe